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▪ 229 million recorded malarial infections annually (2019).
▪ Lethal cases have decreased by ~10% every five years since 2000 (2019).
▪ Malaria burden is highly uneven: Sub-Saharan Africa ~92% of lethal cases (2015)
▪ The R21 (modified RTS,S) vaccine displayed 77% efficacy young children (04/2021)
▪ The malaria-causing plasmodia can readily mutate, meaning there is no one ‘silver-bullet’.
▪ ~80% of lethal malarial cases are related to P. falciparum infection.
▪ Cytochrome bc1 is a dimeric multi-subunit, 
inner mitochondrial, membrane-bound protein
▪ Maintains electrostatic potential, driving ATP 
synthesis.
▪ Atovaquone is the only FDA-approved drug 
targeting the cyt bc1 complex of P. 
falciparum. 
▪ Inhibitor of cyt bc1 at the Qo site
▪ Atovaquone/multi- drug-resistances emerging
Malaria  
Cytochrome bc1 Complex and Atovaquone
Anti-plasmodial Results
Conclusion and Future Directions
References
• SJK-5 and 6 displayed activity 
against D6 (chloroquine-
resistant) and W2 (chloroquine-
senstive) strains. 
• SJK-5 also demonstrated 
activity against Dd2 (multi-drug 
resistant) strain.
• All SJK series displayed activity 
against atovaquone-resistant 
C2B isolates.
• IHK series compounds did not 
exhibit significant anti-
plasmodial activity.
• Combined rational-in silico approach for identified anti-malarial leads
• Antibacterial leads for both P. aeruginosa and methicillin-resistant Staphylococcus aureus were identified
• Our future directions
• Synthesis of 2nd generation antimalarial library based on SJK-5 and 6
• Synthesis of IHK-1 and 4 analogues and assessment of activity against P. aeruginosa and methicillin-
resistant Staphylococcus aureus.
Hypothesis
By analyzing binding interactions between atovaquone and yeast cytochrome bc1 in silico, and highlighting
addition protein-drug interactions not known between atovaquone and cytochrome bc1, potential inhibitors
atovaquone-resistant and multi-drug-resistant P. falciparum strains will be identified.
Figure 1. (A) Binding interactions of atovaquone and yeast cyt bc1. (B) Crystal structure 
of the Qo binding site of  yeast cyt bc1 complex (cyan) with atovaquone bound (yellow).
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Table 1. In vitro anti-plasmodial 












Artemisinin 0.035 0.035 N/A N/A >0.843
Chloroquine 0.024 0.024 N/A N/A >0.744
Atovaquone 8.2 x 10-4 8.2 x 10-4 2.16 x 10-7 9.442 >0.130
SJK-1 8.740 8.740 0.734 0.091 >12.31
SJK-2 1.736 1.736 0.372 0.348 >11.82
SJK-3 0.201 0.201 0.024 0.056 6.437
SJK-4 0.268 0.268 0.107 3.003 >11.92
SJK-5 2.6 x 10-3 2.63 x 10-3 1.83 x 10-7 0.087 >0.125
SJK-6 4.5 x 10-3 4.5 x 10-3 2.93 x 10-7 0.356 >0.125
IHK-1 >4.76 >4.76 N/A N/A >4.76
IHK-2 4.59 >4.76 N/A N/A >4.76
IHK-3 >4.76 3.91 N/A N/A >4.76
IHK-4 >4.76 >4.76 N/A N/A >4.76
IHK-5 >4.76 >4.76 N/A N/A >4.76
IHK-6 >4.76 4.33 N/A N/A >4.76
Compounds MRSa (μM) E. coli (μM) P. aeruginosa (μM) K. pneumoniae (μM) VRE (μM)
FLU >326.51 >326.51 >326.51 >326.51 >326.51
AMB >108.21 >108.21 >108.21 >108.21 >108.21
CIPRO >30.18 <0.03 0.48 >30.18 >30.18
Vanco 0.93 >69.00 >69.00 >69.00 >69.00
METH 27.49 >262.87 135.00 >262.87 >262.87
CEFO 25.07 >219.22 7.99 >219.55 >219.55
MERO 7.65 37.57 32.11 196.50 >260.78
Atovaquone >54.52 >54.52 >54.52 >54.52 >54.52
SJK-1 >51.70 >51.70 >51.70 >51.70 >51.70
SJK-2 >49.65 >49.65 >49.65 >49.65 >49.65
SJK-3 >49.65 >49.65 >49.65 >49.65 >49.65
SJK-4 >50.09 >50.09 >50.09 >50.09 >50.09
SJK-5 >52.51 >52.51 3.20 >52.51 >52.51
SJK-6 >52.51 >52.51 3.47 >52.51 >52.51
IHK-1 1.25 NA NA NA NA
IHK-4 9.00 NA NA NA NA
Table 2. In vitro anti-bacterial 
compound activity including anti-
MRSa activity.
Cytochrome bc1 and Hydroxy-1,4-naphthoquinones
Figure 4. Crystal 
structure of Qo binding 
site of  yeast cyt bc1 
complex (cyan) bound 
to atovaquone (yellow) 
and SJK-3 (pink).  
SJK-3 is also 
interacting with Met 
139. 
Figure 5. Crystal 
structure of Qo binding 
site of yeast cyt bc1 
complex (cyan) bound 
to atovaquone (yellow) 
and SJK-5 (pink). SJK-
5 is also interacting 
with Phe 129 amd Tyr 
137. 
Figure 6. Qo binding 
site of yeast cyt bc1 
complex (cyan) 
bound to atovaquone 
(yellow) and SJK-6
(pink). SJK-6 is also 
interacting with Met 
139 and Ile 269. 
Phenoxy-phenyl-naphthoquinones
Hydroxy-1,4-naphthoquinones




Figure 2. Structure 
of atovaquone, our 
lead for design.
Figure 8. General structure of phenoxy-
phenyl-naphthoquinone compounds, IHK 1-6.
Figure 7. Structure of ELQ-300, a known 
P. falciparum and P. vivax inhibitor. 
After optimizing the naphthoquinone ring 
during design of the SJK series, the IHK 
series was synthesized by employing 
structural elements from a known antimalarial 
along SJK series design elements.
Antibacterial Results
• SJK-5 and 6 displayed 
activity against p. aeruginosa
in vivo
• No other significant efficacy 




• IHK-1 and 4 displayed activity 
against MRSa
• IHK-1 performed similarly 
to vancomycin in vivo.
• No compound leads for E. 
coli, K. penumoniae, or VRE 
were discovered.
Using a crystal structure of a yeast
cytochrome bc1 complex (4PD4), over
30 compounds were explored. Six of the
most promising in silico leads were
synthesized. Three representative poses
are shown below in Figures 4-6.
